Merus Announces Publication Of Abstracts On MCLA-129 For Presentation At ESMO Asia Congress 2023
Portfolio Pulse from Benzinga Newsdesk
Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company, announced the publication of two abstracts on MCLA-129 for presentation at ESMO Asia Congress 2023. The abstracts include interim clinical data from studies on non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). MCLA-129 showed promising results in NSCLC when combined with osimertinib, and modest results as monotherapy in HNSCC. Merus plans to explore further development and potential partnerships for MCLA-129. An abstract on zenocutuzumab for NRG1+ NSCLC will also be presented. An investor call is scheduled for November 27, 2023.
November 27, 2023 | 4:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merus N.V. announced promising interim clinical data for MCLA-129 in NSCLC and modest results in HNSCC, with plans for further development and potential partnerships.
The positive interim clinical data for MCLA-129 in NSCLC could lead to increased investor confidence and potential partnerships, which may have a positive short-term impact on MRUS stock price. The modest results in HNSCC are acknowledged, but the focus on NSCLC and the potential for further development are likely to be viewed favorably by investors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100